1 Time from treatment initiation to HIV viral suppression in public care

2 facilities in Brazil: a nationwide linked databases cohort

3

4	Maria Ines Battistella Nemes ^{1#} , Ana Paula Sayuri Sato ^{2^} , Barbara Reis-Santos ^{1&} , Ana
5	Maroso Alves ^{1*} , Felipe Parra do Nascimento ^{1°} , Bruce Agins ³ "
6	
7 8	¹ Departament of Preventive Medicine, School of Medicine, University of São Paulo, São Paulo, São Paulo, São Paulo, São Paulo, Brazil
9	² Department of Epidemiology, School of Public Health Universidade de São Paulo, University of São
10 11 12	 Paulo, Sao Paulo, Sao Paulo, Brazil. ³ Institute for Global Health Sciences, Division of Epidemiology, University of California, San Francisco, California, United States of America
13	
14 15	*Conceptualization, Supervision, Investigation, Methodology, Data curation, Writing – original draft, Writing – review & editing
16 17	[^] Conceptualization, Formal analysis, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing
18 19	*Conceptualizion, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing
20	"Formal analysis, Visualization, Writing – original draft, Writing – review & editing
21 22	& Visualization, Writing – original draft, Writing – review & editing
23	whiting – original drait, whiting – review & editing
24	Corresponding author
25	e-mail: mibnemes@usp.br (MIBN)
26	
27	
28	
29	

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

Objectives: To analyze the time between antiretroviral therapy (ART) initiation and the first HIV viral load (VL) test <40 copies—time to suppression (TS)—in a cohort of persons aged ≥15 years, between 2015-2018 in outpatient HIV care facilities of the Brazilian Unified Health System, as well as to analyze whether individual and facility characteristics accelerate or delay TS.

37 **Methods:** This was a cohort study with data from a linkage of national HIV databases, following a previously published procedure. Two types of variables were 38 examined: individual-level (sex, age group, race/skin color, education, baseline 39 40 CD4 cell count and VL, initial ART regimen, adherence, ART regimen change and number of VL tests until suppression) and facility-level (national and metropolitan 41 42 region, caseload). Multilevel parametric accelerated failure time survival models were 43 used. Fixed and random effects were analyzed through null, sociodemographic, 44 combined sociodemographic and clinical, and facility-related variables, adjusted for 45 the number of VL tests until suppression. Likelihood, interguartile range, and proportion of change in variance were used for comparisons. 46

Results: Of 132,540 participants, 89.4% (114,696) achieved viral suppression:
20.8% within three months, and 56.4% within six months. Median TS was 161 days,
varying from 31 to 1,426 days, depending on the time interval between initiation and
VL testing. Among those who had VL testing within 66 days, median TS was 55 days.
All individual and facility-related variables were associated with TS, explaining the
16.2% and 13.2% variability, respectively.

53 **Conclusions:** This was the first Brazilian nationwide cohort to analyze TS. It is also 54 one of the largest operational cohorts globally to assess healthcare facility 55 characteristics. The findings indicated that both individual and facility-related 56 characteristics contribute to TS. Strengthening VL monitoring should be included as 57 part of a coordinated effort to improve the quality of care provided for people living with 58 HIV/AIDS in Brazil.

59 Introduction

The clinical and public health benefits of HIV viral load suppression (VS) through 60 61 combination antiretroviral therapy (ART) are well-established, supported by robust scientific evidence[1-4] which forms the basis for policies and strategies that aim to 62 63 engage the international community, governments, and civil society in achieving and maintaining VS targets. Cascade-based official reports from HIV national programs 64 65 [5,6] compile indicators that are immediately useful for healthcare professionals, HIV 66 care facility managers, and system managers[7,8]. These indicators are, however, limited by their cross-sectional design, as they assess the VS proportion of the group 67 of persons in care within a fixed time interval (usually six, 12, or 24 months) between 68 ART initiation and VS achievement, without considering temporal evolution[9]. 69 Acknowledging these limitations, researchers have advocated that the parameter used 70 by HIV programs to monitor ART success be time to VS[10-14]. 71

With widespread use of integrase inhibitors [9], an increase has been seen in studies
examining time to VS continuously[15-20]. As associated factors, a significant portion
of these studies analyze individual characteristics, whereas fewer of them also analyze
care facility characteristics[20-23].

Up to the time of writing this paper, we identified only one population-based crosssectional study in Brazil that assessed the median time between ART initiation and VS, conducted from 2004 to 2018 in one Brazilian state[24]. No study including care facility characteristics in its analysis was, however, found.

This article aimed to analyze the time between ART initiation and first VS in a cohort of persons living with HIV/AIDS (PLWHA) who initiated ART between 2015 and 2018 in outpatient HIV care facilities of the Brazilian Unified Health System (SUS). A further objective was to analyze whether individual characteristics and healthcare facility characteristics accelerate or delay time to VS.

85 Materials and methods

86 Study design

87 This was an observational longitudinal study including PLWHA aged ≥15 years who
88 are participants in the Qualiaids-Brazil Cohort.

89 Context

90 In Brazil, the establishment of the national program for STD/AIDS in 1986[25] prompted the implementation of hospital and outpatient facilities for the treatment of 91 people with AIDS, mostly within pre-existing structures of the public health system[26]. 92 93 which officially became the SUS[27] in 1988. The spread of AIDS in the country and 94 the introduction of ART in 1996, which turned HIV disease into a chronic condition, led to a significant expansion in the number of outpatient facilities, reaching approximately 95 96 1,300 today [28]. These facilities are the exclusive providers of ART medication for approximately 852,000 people. Clinical monitoring of PLWHA can be carried out within 97

the public or private healthcare system. According to the cohort database, it has been
estimated that 69% of PLWHA received outpatient monitoring through SUS
facilities[28,29].

101 Study population

The Qualiaids-Brazil Cohort comprises PLWHA who received treatment at SUS 102 103 facilities that participated as respondents in a national survey regarding facility 104 characteristics (Qualiaids Survey)[30-34]. PLWHA aged ≥15 years were included if 105 they had their first ART dispensation between 2015 and 2018, a CD4 test conducted 106 between 120 days before and 30 days after the first ART dispensation, and at least 107 two viral load (VL) test results. The exclusion criteria considered inconsistencies in PLWHA data among the data sources used. Further information on the construction 108 109 of the database and the profile of the Qualiaids-Brazil Cohort can be obtained from a previous publication[29]. 110

For this study, only PLWHA who were in treatment for more than 30 days were included[35]. This was due both to the inability to assess treatment effect for very early suppressions and the possibility of delays in recording the first dispensation date. Those who had their last VL test in the SUS before their first ART dispensation were excluded.

116 Follow-up

The date of the first medication dispensation was defined as the initiation of ART, and the date of the last VL test was set as the final follow-up date. Deaths and loss to follow-up were classified as censoring events. The mortality data comprised only those

deaths attributed to HIV-related causes[29]. Loss to follow-up was attributed to
individuals who went more than 100 days without picking up medication or having VL
tests until the final follow-up date of the cohort (December 31, 2018)[29].
Administrative censoring referred to individuals who did not achieve VS by the end of
the follow-up period.

125 Study variables

The dependent variable was the time from treatment initiation to VS, defined as the number of days elapsed between the date of the first ART dispensation and the date of the first VL <40 copies/mL after ART initiation. The independent variables included data on individuals and treatment facilities.

130 The following sociodemographic characteristics of individuals were included: sex 131 (female; male), age group (15-19; 20-29; 30-39; 40-49; 50-59; ≥60 years), race/skin color (white; black; vellow; mixed-race; indigenous), and education level (none; 1-3; 4-132 133 7; 8-11; ≥12 years). For the variables race/skin color and education level 7.3% and 134 18.6% of entries were missing data respectively. Therefore, imputation was performed to reduce potential biases in the analyses by using Stata 15's *mi impute mlogit* library, 135 136 which employs a multinomial logistic regression model for imputation of nominal variables. The variable transmission category was excluded due to the high proportion 137 138 of missing records (34.2%) in the original database.

Among individual clinical characteristics, *baseline CD4 lymphocyte count* showed considerable variation within the interval between the date of the test and treatment initiation, as has been reported elsewhere in the literature [36,37]. We thus decided to consider as baseline the CD4 lymphocyte count performed between six months before

and 30 days after the treatment initiation date (<200; 200-349; 350-499; ≥500 143 cells/mm³). The remaining clinical variables included were: *initial VL count* (≤100,000; 144 >100,000 copies/mL) and occurrence of active tuberculosis episode until the first VS 145 146 (no: ves). Regarding treatment, the variable *initial therapeutic regimen* comprised ART medications specified in the clinical protocol of the period: preferred regimens - non-147 nucleoside reverse transcriptase inhibitor + 1 integrase inhibitor (NNRTI+1INI) and 148 149 nucleoside reverse transcriptase inhibitors + 1 non-nucleoside reverse transcriptase inhibitor (2NRTI+1NNRTI); special regimens authorized by regional technical 150 151 chambers and unauthorized regimens[38].

Additionally, the following variables were included: *change in therapeutic regimen until* VS (no; yes), *adherence to treatment until the first VS*, measured by the Medication Possession Ratio - MPR (<80%; 80-94%; \geq 95%), and the *number of VL tests conducted until VS*.

The variables regarding treatment facility characteristics were: *facility location according to geographical region* (North; Northeast; Central-West; South; Southeast), *metropolitan region* (no; yes), and *total number of PLWHA who initiated ART at the facility between 2015-2018* (\leq 50; 51-500; >500).

160 Data analysis

The dependent variable was the distribution of the time from treatment initiation to VS, for which Normal, Log-Normal, Weibull, Exponential, and Gamma distributions were tested[39]. The Log-Normal distribution showed the best fit to the data. We therefore decided to use a parametric multilevel accelerated failure time survival model with a Log-Normal distribution for the analysis of cohort data[40,41].

Initially, the absolute and relative frequencies of the qualitative variables were examined, and measures of central tendency and dispersion were calculated for the dependent (quantitative) variable. Subsequently, bivariate analyses were conducted between the dependent variable and each individual and facility-related variable. Finally, these variables were analyzed in multiple hierarchical models. The two levels of aggregation in the models (individual and facility-related) and the hierarchy of variables were defined based on the theoretical model presented in Figure 1.



173

Fig 1. Theoretical model of clinical outcome production in HIV infection
 treatment

(a) Ministry of Health systems for continuous information recording: SINAN, SIM,

177 SICLOM, SISCEL. (b) 2017 and 2023 nationwide Qualiaids surveys

178 Four models were constructed for the multiple analysis, aiming to measure the fixed

and random effects of the variables at each level. Based on the null model, individual

180 variables were included in the following sequence: sociodemographic characteristics,

disease severity, and treatment. The model relative to treatment facilities included only

the block of facility-related variables. Comparisons between the models were conducted using likelihood, interquartile range, and the proportion of change in variance. The results were presented as time ratios (TR) and their respective 95% confidence intervals (95% CI). The significance level used for all analyses was 5%.

186 For the characterization of random effects, the four analyzed models were compared

187 in terms of random variance (standard error-SE), intraclass correlation coefficient

188 (ICC), log likelihood, and proportional change in variance (PCV)[42-45].

189 The PCV, at the contextual level, measures the variation of time to VS across 190 healthcare facilities and is defined as[42,43,45]:

191
$$PCV = \frac{\text{Random variance of the null model} - \text{random variance of the final model}}{\text{Random variance of the null model}}$$

192 Contextual differences in time to VS can be attributed to random effects or differences 193 in individual composition of the facilities in terms of sociodemographic factors, disease 194 severity, or treatment initiation of the patients. Therefore, the PCV was calculated by 195 comparing the null model with the other models that included only individual variables 196 (models 1 and 2) and only facility-related variables (model 3).

The ICC is the proportion of the total variance of time to VS among treatment facilities that is attributed to facility variability; in other words, it measures the heterogeneity of time to VS attributed to differences between facilities, and is calculated for each model using the formula[44]:

201
$$ICC = \frac{\text{Random variance}}{\text{Random variance} + \text{individual variance}}$$

As detected in observational[24,46-50] studies, there has been variation in adherence to the VL monitoring protocol, which may affect the estimates[46-51]. To minimize this limitation, all models were adjusted for the number of VL tests received by the individual.

Additionally, a sensitivity analysis was conducted by replicating the models with the inclusion of the variable *transmission category*, using the subset of individuals with complete information for this variable (Supplementary Table 2), and without adjustment for the number of VL tests received (Supplementary Table 3). All analyses were performed using Stata 15.0's *mestreg* package.

211 Ethical considerations

The project was approved by the Ethics Committee on Research on Human Beings of the USP School of Medicine on January 23, 2020 (CAAE: 27659220.3.0000.0065; Opinion: 3.807.435), following the recommendations of Resolution No. 466 of 2012 from the Brazilian National Health Council. The data was sent to the research team on May 10, 2020. There were no variables or information that could identify the individuals in the data set received.

218 **Results**

The Qualiaids-Brazil Cohort comprises 132,540 PLWHA who initiated ART in Brazil between January 1, 2015, and December 31, 2018. For this study, considering eligibility criteria, 128,360 PLWHA were included who had been in treatment for more than 30 days and received at least one VL test after starting ART. A total of 2,544 (1.9%) individuals who had been in treatment for fewer than 30 days, and 1,636 (1.2%) individuals who did not receive a VL test before the first ART dispensation were

- excluded. The censoring events were as follows: 1,496 (1.1%) deaths, 3,838 (2.9%)
- losses to follow-up, and 10,988 (8.3%) administrative censorings[29].
- 227 The distribution of time to VS is shown in Figure 2. Of the PLWHA considered in this
- study, 89.4% (114,696) achieved VS, with 20.8% (23,801) reaching it within 3 months
- after treatment initiation, 56.4% (64,636) within 6 months, and 87.5% (100,408) within
- 230 12 months.



²³¹

The median time to VS for all included individuals was 161 days, ranging from 31 to

1,426 days, depending on the time interval between treatment initiation and the control

237 VL test. Shorter intervals resulted in smaller medians (Supplementary Table 1).

238 Regarding the distribution of individual characteristics of the participants, higher

- proportions of PLWHA were identified as male (69.8%), aged 20-39 years (64.3%),
- with >8 years of schooling (62.8%), and of race/skin color brown or black (54.6%). A

Fig 2. Distribution of time to VS, in days, Qualiaids-Brazil Cohort, 2015-2018 (N
 = 128,360)

total of 26% of participants had an initial CD4 count <200 cells/mm³, whereas initial VL >100,000 copies/mL was observed in 8.2% of participants. The initial therapeutic regimen was 2NRTI + 1NNRTI for 61.8% of participants; 3.2% changed their therapeutic regimen before the first VS. 42.5% of participants experienced an episode of tuberculosis before the first VS. 42.5% of participants had treatment adherence rates of \geq 95%.

Regarding the treatment facilities, Figure 3 shows the distribution of the 941 included facilities and of PLWHA monitored in them, according to geographic region and location in metropolitan areas. The Southeast region accounted for most facilities (59.0%) and PLWHA (41.2%). There was a predominance of facilities located in capital cities or metropolitan regions (66.2%) and facilities assisting 51-500 individuals who started ART during the period (49.0%).



0	E	2
2	Э	3

Total

Fig 2. SUS HIV treatment facilities and number of individuals included in the cohort
 who initiated ART in 2015-2018, categorized by macro-region of the country.
 Qualiaids-Brazil Cohort, 2022 (N=941)

100.0

45 100.0

555 100.0

178 100.0

941 100.0

100.0 123

40

257

Table 1 shows the observed proportions of individual characteristics and the bivariate

- analyses between the dependent variable and each of the individual variables
- 260 (sociodemographic, clinical, and treatment-related).

Table 1. Descriptive analysis and bivariate analysis of the time from treatment initiation to VS, according to individual variables. Qualiaids-Brazil Cohort,

263 **2015-2018 (N = 128.360)**

	,				
Variable		Total	%	Bivariate	

			Suppression*	Time Ratio	LT	HT
Sex						
Male	89,586	69.8	89.5	ref		
Female	38,774	30.2	88.9	0.93	0.93	0.94**
Age group (in years)						
15-19	5,761	4.5	87.1	1.04	1.02	1.07**
20-29	44.823	34.9	89.7	1.01	0.99	1.02
30-39	37,672	29.4	88.8	1.03	1.02	1.05**
40-49	23 214	18.1	89.2	1 03	1 02	1 05**
50-59	12 081	94	90.4	ref		
>60	4 809	3.8	91.3	0.98	0.96	1 01
Bace/skin color	1,000	0.0	01.0	0.00	0.00	1.01
White	57 183	44 5	91.0	ref		
Black	1/ 181	11 1	87.8	1 0/	1 0 2	1 05**
Vollow	052	07	07.0	1.04	0.02	1.00
Prown	900	0.1 12 E	00.9	1.03	0.90	1.09
	071	43.5	00.2	1.04	1.03	CU.I
Indigenous Extra time (in an and a fractional line)	271	0.2	79.3	1.22	1.11	1.34
Education (in years of schooling)	0.070	4.0	00 7	4.40		4 00**
None	2,278	1.8	86.7	1.18	1.14	1.22**
1-3	11,132	8.7	85.6	1.21	1.19	1.24**
4-7	34,298	26.7	86.9	1.17	1.16	1.19**
8-11	52,042	40.5	90.1	1.07	1.06	1.08**
≥12	28,610	22.3	92.5	ref		
Initial therapeutic regimen						
Preferred regimen (2017-2018: NNRTI+1INI)	48,410	37.7	89.6	ref		
Preferred regimen (2015-2016: 2NRTI +	70 288	61.8	80.3	1 54	1 53	1 55**
1NNRTI)	13,200	01.0	03.5	1.54	1.55	1.55
Authorized special regimens	118	0.1	83.1	1.39	1.21	1.60**
Unauthorized regimens	544	0.4	85.7	1.48	1.39	1.58**
Initial CD4 lymphocyte count (cells/mm ³)						
<200	33,327	26.0	82.7	1.33	1.31	1.35**
200-349	25,054	19.5	89.1	1.14	1.13	1.15**
350-499	26.329	20.5	91.6	1.07	1.05	1.08**
≥500	43.650	34.0	93.2	ref		
Initial VL count (copies/mL)	-,			-		
≤100 000	117 864	91.8	91 9	ref		
>100,000	10 496	8.2	82.6	1.39	1.38	1 40**
Active tuberculosis episode until suppression	10,100	0.2	02.0			
No	122 014	95 1	90.2	ref		
Yes	6 346	<u>4</u> 9	72 9	1 45	1 4 2	1 48**
Thorapoutic regimon change before	0,540	- .5	12.5	1.40	1.72	1.40
suppression						
Νο	12/ 205	96 90	80.0	rof		
Voo	124,303	ອບ.o ວ່າ	100.0		1 4 0	1 10**
105	4,000	J.Z	100.0	1.40	1.42	1.49
	E4 040	40 5	00.0	Def		
<₩30%	54,618	42.5	92.6	Ket	4.00	A A 4 4-1-
80-95%	66,334	51.7	89.4	1.40	1.39	1.41**
<80%	7,408	5.8	65.4	2.17	2.12	2.21**

264 * Chi-square p<0.05 for all variables **P≤0.001

Table 2 shows the bivariate analysis between the dependent variable and each of the

266 facility-related variables.

Table 2. Bivariate analysis of the time between treatment initiation and VS, according to facility-related variables. Qualiaids-Brazil Cohort, 2015-2018 (N = 128,360)

Variable	TR (95% CI)
Geographic region	
Central-West	1.10[1.03;1.18]
North	1.13[1.06;1.21]
Northeast	1.14[1.09;1.19]
South	0.99[0.96;1.04]
Southeast	Ref
Facility location (municipality)	
Metropolitan region	Ref
Other	1.09[1.05;1.12]
Number of patients served	
≤50	1.15[1.09;1.21]
51-500	1.03[0.98;1.07]
>500	Ref

271

272 The bivariate analysis showed that PLWHA who received care in facilities in the North

273 (TR = 1.13; 95% CI: 1.06; 1.21), Northeast (TR = 1.14; 95% CI: 1.09; 1.19), and

274 Central-West (TR = 1.10; 95% CI: 1.03; 1.18) regions had a longer time to VS

275 compared to those in the Southeast. This finding was also observed for PLWHA

treated in facilities located outside the metropolitan region (TR = 1.09; 95% CI: 1.05;

1.12) and in facilities serving <50 PLWHA (TR = 1.15; 95% CI: 1.09; 1.21).

278 The variables were then analyzed in the multiple models (Table 3). The time ratios of

- 279 individual and facility-related variables in the multiple models followed the same
- 280 direction as in the bivariate models.

Table 3. Results of hierarchically adjusted multilevel models for time to VS, according to individual and facility-related characteristics, Qualiaids-Brazil Cohort, 2015-2018 (N = 128,360)

Variable	TR (95% CI)
Sex Male Female Age group (in years) 15-19 20-29 30-39 40-49 50-59 ≥60 Race/skin color	ref 0.91[0.90;0.92] 1.14[1.11;1.16] 1.08[1.07;1.10] 1.06[1.04;1.07] 1.03[1.02;1.05] Ref 0.97[0.95;1.00]

	White	Ref
	Black	1.04[1.02;1.05]
	Yellow	1.01[0.97;1.06]
	Brown	1.03[1.02;1.04]
	Indigenous	1.17[1.07;1.27]
	Education (in years of schooling)	1 10[1 11.1 01]
	1-3	1.10[1.14,1.21]
	4-7	1.15[1.14:1.16]
	8-11	1.06[1.05;1.07]
	≥12	Ref
	Initial therapeutic regimen	
	Preferred regimen (2017-2018: NNRTI+1INI)	Ref
	Preferred regimen (2015-2016: 2NRTI + 1NNRTI)	1.33[1.32;1.34]
	Authorized special regimens	1.07[0.94;1.21]
	Unauthorized regimens	1.23[1.16;1.31]
		1 00[1 08.1 10]
	200-349	1.09[1.00,1.10]
	350-499	1.03[1.00,1.10]
	≥500	Ref
	Initial VL count (copies/mL)	
	≤100,000	Ref
	>100,000	1.19[1.17;1.20]
	Active tuberculosis episode until suppression	. .
	No	Ret
	res Therapoutic regimen change	1.10[1.08,1.12]
	No	Ref
	Yes	1.15[1.13:1.18]
	Adherence	
	≥95%	Ref
	80-95%	1.19[1.18;1.21]
	<80%	1.83[1.79;1.86]
	Geographic region	1 10[1 00.1 00]
	Central-west	1.18[1.08,1.28]
	Northeast	1.20[1.11,1.30]
	South	1 01[0 97:1 06]
	Southeast	Ref
	Facility location (municipality)	-
	Metropolitan region	Ref
	Other	1.06[1.02;1.10]
3	Number of patients served	
de	≤5U	1.15[1.05;1.26]
Mo	51-500 >500	0.96[0.89;1.04]
	-300	Rei

Legend: Model 1 – sociodemographic characteristics; Model 2 – sociodemographic + clinical
 characteristics; Model 3 – facility-related characteristics.

All models were adjusted for the number of VL tests performed until VS.

Among individual variables, the following were associated with longer time to VS: male

sex; age below 50 years; Black and Brown, race/skin color; education ≤11 years of

schooling; therapeutic regimen 2NRTI + 1NNRTI; authorized special regimens or 290 291 unauthorized regimens; initial CD4 count <500 cells/mm³; initial VL >100,000 292 copies/mL; active tuberculosis episode; therapeutic regimen change; and treatment 293 adherence <95%. Regarding the characteristics of treatment facilities. PLWHA who received care in facilities in the North, Northeast, and Central-West regions had a 294 longer time to VS. The same was observed for PLWHA assisted by facilities located 295 296 outside the metropolitan region (TR = 1.06; 95% CI: 1.02; 1.10) and by facilities 297 attending <50 PLWHA (TR = 1.15; 95% CI: 1.05; 1.26).

298 Table 4 shows the difference in unexplained variability for each model. Model 2 showed the lowest unexplained variability, which is consistent with its higher number 299 300 of explanatory variables. The model adjusted for facility-related variables (model 3) 301 exhibited the lowest ICC (7.7%), indicating that this adjustment was able to reduce 302 heterogeneity in time to VS. Furthermore, it was observed that 16.2% of the variability 303 in time to VS was explained by individual sociodemographic and clinical variables 304 (model 2); however, 13.2% of this variability can be explained solely by the facilityrelated variables. The log likelihood indicated that model 2 was the best fit. 305

Table 4. Results of the random-effects analysis of models null through 3, Qualiaids-Brazil Cohort, 2015-2018 (N = 128,360)

308

	Null Model	Model 1	Model 2	Model 3
Random Variance	0.068	0.066	0.057	0.059
(SE)	(0.004)	(0.004)	(0.003)	(0.003)
ICC	0.093	0.091	0.083	0.077
PCV	ref	0.029	0.162	0.132
Log Likelihood	-712903.7	-712188.3	-706630.4	-712830.4

309 SE: standard error; ICC: intraclass correlation coefficient; PCV: proportional change in variance

310 The results of the sensitivity analyses were consistent with the findings, showing small

311 variations in effect estimates (Supplementary Tables 2 and 3).

312 **Discussion**

Among PLWHA participating in the Qualiaids-Brazil Cohort who initiated ART in SUS healthcare facilities between 2015 and 2018, nearly 90% achieved VS, half of whom did so within five months of treatment.

Individuals in the following categories had a higher proportion of VS during the cohort's time period: male sex, aged 50-59 years, white race/skin color, with \geq 12 years of education, initial treatment regimen NNRTI+1INI, initial CD4 lymphocyte count \geq 500 cells/mm³, initial VL count \leq 100,000 copies/mL, without an active tuberculosis episode, without therapeutic regimen change, with \geq 95% adherence to treatment, and receiving clinical follow-up in facilities located in the Southeast or South regions, in metropolitan areas, and in facilities serving \geq 500 PLWHA.

Individual variables accounted for most of the variability in time to VS; however, facility related variables also played a noteworthy role.

Regarding individual characteristics, there was an association with longer time to VS of individuals of brown and black race/skin color, as well as those with lower education levels. In Brazil, these characteristics are proxies for poorer social conditions[52]. This finding is consistent with several international studies on ethnic and social disparities[53-56].

Social issues are intertwined with clinical issues. The study demonstrated that late diagnosis, with a low CD4 level (<200) and very high VL (>100,000), delays time to VS, echoing numerous studies that associate these factors with negative outcomes. Since 2015, Brazil has maintained a late diagnosis proportion of around 25%[8]. The trends observed in countries with similar epidemic profiles also confirm the maintenance of late diagnosis proportions. Globally, it is still observed that the

proportion of people diagnosed late is changing little as the effectiveness of ARTcontinues to improve[10,57-59].

338 In Brazil, especially, the second most important clinical condition associated with 339 negative outcomes is tuberculosis (TB). This situation is similar to that of low-income 340 countries, where TB is the leading cause of death among PLWHA, notably in the first 341 year after diagnosis[60,61]. Brazil is among the 12 countries with the highest global 342 TB burden. Regarding coinfection HIV and tuberculosis, it has the highest burden of those countries[62]. Coinfection with TB is associated with lower CD4 levels and 343 344 higher VL levels, underscoring the importance of HIV treatment facilities in diagnosing and treating both latent and active tuberculosis [63,64]. 345

The negative impact on time to VS resulting from poor adherence to HIV treatment reaffirms numerous studies that, since the HIV treatment became available, have emphasized the crucial role of promotion, monitoring, and support by treatment facilities for those with difficulty in adhering to the prescribed regimen [65,66].

350 The longer time to achieving VS among non-white individuals with lower education 351 levels follows the general trend highlighted in studies of mortality, late diagnosis, loss 352 to follow-up, and tuberculosis, reflecting social and ethnic inequality in the country. 353 Despite significant progress in addressing the HIV epidemic through free and universal 354 access to high-effectiveness care and medication across the country, the healthcare system has not successfully mitigated inequalities to achieved desired health 355 356 outcomes, reflecting disparities in the allocation and organization of treatment 357 facilities. The higher concentration of facilities in the Southeast and South regions and 358 in metropolitan areas corresponds to the greater concentration of PLWHA in these 359 locations. Certainly, there is also a need for smaller facilities, particularly in smaller

360 cities within the regions. On the other hand, the allocation of facilities in both large and small municipalities for a small number of patients (<50) appears to be problematic. 361 care 362 suggesting significant diversity of HIV policies among municipal 363 administrations[28,67]. While certain geographical conditions may warrant the establishment of small-scale facilities, evidence repeatedly shows a higher likelihood 364 of negative outcomes in facilities with a reduced number of patients [21,68]. Balancing 365 366 easy access to treatment with professional training and organization therefore is an important priority to ensure appropriate guality of care. Disparities in the organization 367 368 of HIV care at regional, district, and even municipal levels have been highlighted in national studies[31-34,69,70]. 369

370 The study revealed a significant flaw in the quality of the care provided by treatment 371 facilities: among PLWHA who achieved VS during the study period, 67.2% did not 372 receive VL testing within the timeframe specified by the protocol (66 days)[38]. The 373 deficiency in monitoring has been pointed out in studies of the records of two populous Brazilian states, Minas Gerais[24] and Rio de Janeiro[47]. The issue appears to be 374 375 predominantly organizational in nature rather than caused by supply of tests since 376 data indicate high and uniform availability of VL tests across the country's public 377 service network [33, 34]. On the other hand, the request for VL tests and scheduling of follow-up appointments, lacks managerial mechanisms, such as electronic control 378 379 of appointment scheduling and tests rather than relying on individual physician's 380 request tests. We suggested that this flaw in monitoring, translated into longer-than-381 recommended intervals between tests, stems from the high demand for medical 382 appointments—a common issue in larger facilities — thus influencing physicians' 383 decisions regarding test and appointment scheduling. Another possibility is that the 384 longer intervals may be a recommendation from facility managers to alleviate the

385 pressure of demand for appointments. Detailed studies focusing on the organizational 386 processes in treatment facilities are needed to support interventions capable of 387 improving this situation as guickly as possible.

Promptness in having the first VL test after treatment initiation is fully justified by the 388 389 clinical need for timely detection of viral failures and adherence issues[1,71]. It may 390 also operate as an incentive to maintain adherence for those who achieve rapid VS[72,73]. Proper VL monitoring and rapid VS rate are indicators of quality of care[12]. 391 392 The ability to quickly achieve VS is feasible given the effectiveness of available ART 393 regimen, especially for those who initiate treatment with CD4>200 and low VL and maintain good adherence. ART effectiveness has increased with widespread use of 394 395 regimens containing integrase inhibitors, especially dolutegravir [74], which is part of 396 the recommended regimen for treatment initiation in Brazil. There is also repeated 397 evidence that rapid treatment initiation accelerates time to VS[75,76]. However, the

time to initiation could not be addressed in this study.

The median time to VS was 55 days for those who had the first VL test after starting treatment within the established timeframe (66 days). The median is similar to that found in observational studies conducted in locations with a comparable epidemic profile to Brazil's (concentrated epidemic) and with free access to treatment, such as Atlanta, 2016 (57 days)[77], and London, 2018 (56 days)[78].

404 Considering the importance of rapid suppression, Xia[54] and Dombrowski[12] 405 suggested that the treatment time parameter for estimating the "suppressed" bar of 406 the cascade—usually set at 12 months or, as in Brazil, at six months—be reduced to 407 three months. They argue that rapid initiation and the high efficacy of current ART 408 shorten this time, as exemplified by studies that, using a VL threshold of <200

409 copies/mL in three months, found VS proportions of 37%[54] and 45%[17]. With a 410 lower threshold of <50 copies/mL, the proportion of those who achieved VS, in this 411 study, within the shortest evaluated interval (66 days - 27.5%) would likely be higher 412 if the monitoring protocol had been adhered to for most PLWHA. Among all those who 413 achieved VS and were tested within the first three months, VS rate was 36.1%, 414 indicating that it would be possible in Brazil to shorten the threshold to three months, 415 even as an incentive for improving VL monitoring.

This study was the first nationwide cohort, based on a longitudinal database, that analyzed time to VS in PLWHA receiving treatment in the SUS. It was also one of the largest operational cohorts in the international literature. The inclusion of the characteristics of healthcare facilities in the analyses reinforces the study's originality. As time to VS may be influenced by the number of VL tests conducted during the period, the inclusion of this variable in the analyses is also a strength to be noted.

422 Nonetheless, there are were limitations to our analysis. First, in the studied database 423 there was no explicit definition of the healthcare system in which PLWHA received 424 care. Thus, a previously published standardized classification strategy, as defined in the methods section, was employed to minimize that limitation. It should also be noted 425 426 that the use of secondary sources such as developed for operational purposes, 427 involves inconsistencies and missing data, which may lead to misclassification errors 428 and underestimation of the measures of interest. However, the definition of inclusion criteria sensitive to potential inconsistencies and the imputation of data for relevant 429 variables reduces the possibility of interference in the results [29]. 430

This study of a large cohort of PLWA in Brazil was the first to analyze time to viralsuppression and the first to include characteristics of healthcare facilities. The results

strongly suggest the need for more comprehensive longitudinal studies, including
more individual and health facilities characteristics, that can further contribute to
healthcare policies for PLWHA in Brazil.

While acknowledging the limitations, the findings seem sufficient to indicate the urgency of improving VL monitoring in the treatment facilities network across the country. This must be carried out as part of a coordinated effort to provide more equitable access and capacity for HIV facilities to optimize quality care and reduce time to viral suppression.

the quality of care provided to PLWHA nationwide.

442 **References**

445

- INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund
 B, Sharma S, et.al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV
- 446 2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N,

Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816.

- et.al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med.
 2016 Sep 1;375(9):830-9. doi: 10.1056/NEJMoa1600693.
- 449 3. Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV
 450 infection: undetectable equals untransmittable. Jama. 2019 Feb 5;321(5):451-2
- 451
 4. Broyles LN, Luo R, Boeras D, Vojnov L. (2023). The risk of sexual transmission of HIV
 452
 453
 402(10400), 464–471. https://doi.org/10.1016/S0140-6736(23)00877-2
- 454 5. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of
 455 engagement in HIV care and its relevance to test-and-treat strategies for prevention of
 456 HIV infection. Clin Infect Dis. 2011;52:793–800. doi: 10.1093/cid/ciq243
- 457 6. Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum:
 458 updates, goals, and recommendations for the future. AIDS Res Ther. 2016 Nov
 459 8;13:35. doi: 10.1186/s12981-016-0120-0. PMID: 27826353; PMCID: PMC5100316.

- 460 7. World Health Organization. Regional Office for the Eastern Mediterranean. (2014). HIV
 461 test-treat-retain cascade analysis: guide and tools. World Health Organization.
 462 Regional Office for the Eastern Mediterranean.
 463 https://iris.who.int/handle/10665/250533
- 8. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente.
 Departamento de HIV/Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente
 Transmissíveis (DATHI). Relatório do Monitoramento Clínico do HIV 2022, Brasília DF 2023
- 468 9. Haber N, Pillay D, Porter K, Bärnighausen T. (2016). Constructing the cascade of HIV
 469 care: methods for measurement. Current opinion in HIV and AIDS, 11(1), 102–108.
 470 https://doi.org/10.1097/COH.0000000000212
- 471 10. Crepaz N, Ruiguang SO, HALL HI. Estimated time from HIV infection to diagnosis and
 472 diagnosis to first viral suppression during 2014–2018. AIDS (London, England). 2021
 473 Nov 11;35(13):2181.
- 474 11. Vourli G, Katsarolis I, Pantazis N, Touloumi G. HIV continuum of care: expanding
 475 scope beyond a cross-sectional view to include time analysis: a systematic review.
 476 BMC Public Health 21, 1699 (2021). https://doi.org/10.1186/s12889-021-11747-z
- 477 12. Dombrowski JC, Baeten JM. It's Time to Make the Time to Viral Suppression After HIV
 478 Diagnosis a Metric of HIV Care Success. J Infect Dis. 2019;219(6):845-847.
 479 doi:10.1093/infdis/jiy539
- 480 13. Shoemaker ES, Becker ML, Liddy CE, McClarty LM, Asghari S, Hurd J, et.al. Creating
 481 clinical cohorts: challenges encountered in two Canadian provinces. Healthc Policy.
 482 2019;15(1):10–8.
- 14. Liu J, Wilton J, Sullivan A, Marchand-Austin A, Rachlis B, Giles M, et.al. Ontario HIV
 Epidemiology and Surveillance Initiative (2019). Cohort profile: Development and
 profile of a population-based, retrospective cohort of diagnosed people living with HIV
 in Ontario, Canada (Ontario HIV Laboratory Cohort). BMJ open, 9(5), e027325.
 https://doi.org/10.1136/bmjopen-2018-027325

488 15. Bacon O, Chin J, Cohen SE, Hessol NA, Sachdev D, et.al. Decreased Time From
489 Human Immunodeficiency Virus Diagnosis to Care, Antiretroviral Therapy Initiation,
490 and Virologic Suppression during the Citywide RAPID Initiative in San Francisco. Clin
491 Infect Dis. 2021 Jul 1;73(1):e122-e128. doi: 10.1093/cid/ciaa620

- 492 16. Nanditha NGA, Dong X, Tafessu HM, Wang L, Lu M, Barrios R, et.al. (2022). A
 493 province-wide HIV initiative to accelerate initiation of treatment-as-prevention and
 494 virologic suppression in British Columbia, Canada: a population-based cohort study.
 495 CMAJ open, 10(1), E27–E34. https://doi.org/10.9778/cmajo.20210093
- 496 17. Alejos B, Díez C, Galindo MJ, López JC, Moreno-García E, Estrada V, et.al. (2022).
 497 Progress in the quality of care for newly diagnosed people with HIV in Spain (2004498 2019). Antiviral therapy, 27(4), https://doi.org/10.1177/13596535221112729
- 18. Pyngottu A, Scherrer AU, Kouyos R, Huber M, Hirsch H, Perreau M, et.al. Swiss HIV
 Cohort Study. Predictors of Virological Failure and Time to Viral Suppression of FirstLine Integrase Inhibitor-Based Antiretroviral Treatment. Clin Infect Dis. 2021 Oct
 5;73(7):e2134-e2141. doi: 10.1093/cid/ciaa1614.
- 503 19. Huang SW, Shen MC, Wang WH, Li WY, Wang JH, Tseng CY, et.al. High prevalence
 504 of HIV-1 transmitted drug resistance and factors associated with time to virological
 505 failure and viral suppression in Taiwan. J Antimicrob Chemother. 2021 Dec
 506 24;77(1):185-195. doi: 10.1093/jac/dkab361.
- 507 20. Monroe AK, Happ LP, Rayeed N, Ma Y, Jaurretche MJ, Terzian AS, et.al. Clinic-Level
 508 Factors Associated With Time to Antiretroviral Initiation and Viral Suppression in a
 509 Large, Urban Cohort. Clin Infect Dis. 2020 Oct 23;71(7):e151-e158. doi:
 510 10.1093/cid/ciz1098.
- 511 21. Wiewel EW, Borrell LN, Jones HE, Maroko AR, Torian LV. (2019). Healthcare facility
 512 characteristics associated with achievement and maintenance of HIV viral suppression
 513 among persons newly diagnosed with HIV in New York City. AIDS care, 31(12), 1484–
 514 1493. https://doi.org/10.1080/09540121.2019.1595517

515 22. Badejo O, Noestlinger C, Jolayemi T, Adeola J, Okonkwo P, Van Belle S, et.al.
516 Multilevel modelling and multiple group analysis of disparities in continuity of care and
517 viral suppression among adolescents and youths living with HIV in Nigeria. BMJ Glob
518 Health. 2020 Nov;5(11):e003269. doi: 10.1136/bmigh-2020-003269

- 519 23. Sarrazin VMS, Ohl ME, Richardson KK, Asch SM, Gifford AL, Bokhour BG. (2018).
 520 Patient and Facility Correlates of Racial Differences in Viral Control for Black and White
 521 Veterans with HIV Infection in the Veterans Administration. AIDS patient care and
 522 STDs, 32(3), 84–91. https://doi.org/10.1089/apc.2017.0213
- 523 24. Mendicino CCP, Silva GJD, Braga LP, Colosimo EA, Guimarães MDC, Pádua CA M.
 524 (2020). Monitoring HIV infection in Minas Gerais state: 15-year assessment of adults
 525 living with HIV initiating Antiretroviral Therapy. Revista da Sociedade Brasileira de
 526 Medicina Tropical, 53, e20200360. https://doi.org/10.1590/0037-8682-0360-2020
- 527 25. Greco DB, Simão M. Brazilian policy of universal access to AIDS treatment:
 528 sustainability challenges and perspectives. AIDS. (2007) Jul;21 Suppl 4:S37-45. doi:
 529 10.1097/01.aids.0000279705.24428.a3

530 26. Basso CR. Programa de DST/AIDS no SUS. In: Negri B, Viana ALD, organizadores. 531 O Sistema Único de Saúde em 10 anos de desafio. São Paulo: Sobravime; 2002. p. 532 43-58

- 27. Castro MC, Massuda A, Almeida G, Menezes-Filho NA, Andrade MV, de Souza
 Noronha KVM, et.al. Brazil's unified health system: the first 30 years and prospects for
 the future. The Lancet. 2019 Jul 27;394(10195):345-356. doi: 10.1016/S01406736(19)31243-7. Epub 2019 Jul 11
- 28. Alves AM, Santos ACD, Kumow A, Sato APS, Helena ETS, Nemes MIB. Beyond
 access to medication: the role of SUS and the characteristics of HIV care in Brazil. Rev
 Saude Publica. 2023 Apr 17;57:26. doi: 10.11606/s1518-8787.2023057004476. PMID:
 37075422; PMCID: PMC10118421.
- 541 29. Sato APS, Nemes MIB, Alves AM, Souza EL, Santos BDR, Nunes LO, et.al. Profile of
 542 the cohort of people being treated for HIV infection in the SUS, Brazil, 2015-2018. Rev

543 Saude Publica. 2023 Oct 20;57:66. doi: 10.11606/s1518-8787.2023057005256. PMID:
544 37878852; PMCID: PMC10519680.

- 30. Nemes MIB, Castanheira ERL, Loch AP, Santos MA, Alves AM, Melchior R, et al.
 Avaliação de serviços de saúde: a experiência do Qualiaids. In: Akerman M, Furtado
 JP, organizadores. Práticas de avaliação em saúde no Brasil Diálogos. Porto Alegre,
 RS: Rede Unida; 2016 [citado 12 nov 2021]. p. 92-145. Available on:
- 549 http://historico.redeunida.org.br/editora/biblioteca-digital/serie-atencao-basica-e-
- 550 educacao-na-saude/praticas-de-avaliacao-em-saude-no-brasil-dialogos-pdf
- 31. Melchior R, Nemes MIB, Basso CR, Castanheira ERL, Alves MTSSB, Buchala CM, et
 al. Evaluation of the organizational structure of HIV/AIDS outpatient care in Brazil. Rev
 Saude Publica. 2006;40(1):143-51. https://doi.org/10.1590/S003489102006000100022
- 32. Nemes MIB, Alves AM, Loch AP. Sistema de avaliação Qualiaids. São Paulo:
 Faculdade de Medicina da USP, Departamento de Medicina Preventiva; 2016 [cited
 on May 2024]. Available on: https://equipequaliaids.wixsite.com/qualiaids
- 33. Nemes MIB, Alencar TMD, Basso CR, Castanheira ERL, Melchior R, Alves MTSSB,
 et al. Assessment of outpatient services for AIDS patients, Brazil: comparative study
 2001/2007. Rev Saude Publica. 2013;47(1):137-46. https://doi.org/10.1590/S003489102013000100018
- 34. Loch AP, Nemes MIB, Santos MA, Alves AM, Melchior R, Basso CR, et al. Evaluation
 of outpatient services in the Brazilian Unified National Health System for persons living
 with HIV: a comparison of 2007 and 2010. Cad Saúde Pública [Internet].
 2018;34(2):e00047217. Available on: https://doi.org/10.1590/0102-311X00047217
- 35. Buchbinder SP, Havlir DV. Getting to Zero San Francisco: A Collective Impact
 Approach. J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3(Suppl 3):S176-S182.
 doi: 10.1097/QAI.0000000002200.

36. The Late Presentation Working Groups in Euro SIDA and COHERE. Estimating the
burden of HIV late presentation and its attributable morbidity and mortality across
Europe 2010–2016. BMC Infect Dis 20, 728 (2020

- 572 37. Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, et.al. Long-term trends in
- 573 CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy:
- 574 UK Collaborative HIV Cohort (CHIC) study. HIV Med. 2011 Nov;12(10):583-93. doi:
- 575 10.1111/j.1468-1293.2011.00929.x.
- 38. Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de
 Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do
 HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para
 Manejo da Infecção pelo HIV em Adultos. Brasília (DF); 2018 [citado 1 nov 2021].
 Available on: http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizesterapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos
- 582 39. Colosimo EA, Giolo S. Análise de sobrevivência aplicada. São Paulo: Blucher, c2006.
 583 367p

40. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med. 1992 Oct-Nov;11(14-15):1871-9. doi: 10.1002/sim.4780111409

- 587 41. Birhan H, Derebe K, Muche S, Melese B. Statistical Analysis on Determinant Factors
 588 Associated with Time to Death of HIV/TB Co-Infected Patients Under HAART at Debre
 589 Tabor Referral Hospital: An Application of Accelerated Failure Time-Shared Frailty
 590 Models. HIV AIDS (Auckl). 2021 Jul 17; 13:775-787. doi: 10.2147/HIV.S319745.
- 42. Merlo J, Chaix B, Yang M, Lynch J, Råstam L. A brief conceptual tutorial of multilevel
 analysis in social epidemiology: linking the statistical concept of clustering to the idea
 of contextual phenomenon. J Epidemiol Community Health. 2005 Jun;59(6):443-9. doi:
 10.1136/jech.2004.023473.
- 43. Merlo J, Yang M, Chaix B, Lynch J, Råstam L. A brief conceptual tutorial on multilevel
 analysis in social epidemiology: investigating contextual phenomena in different

597 groups of people. J Epidemiol Community Health. 2005 Sep;59(9):729-36. doi:
598 10.1136/jech.2004.023929.

- 44. Merlo J, Chaix B, Ohlsson H, Beckman A, Johnell K, Hjerpe Pet.al. A brief conceptual
 tutorial of multilevel analysis in social epidemiology: using measures of clustering in
 multilevel logistic regression to investigate contextual phenomena. J Epidemiol
 Community Health. 2006 Apr;60(4):290-7. doi: 10.1136/jech.2004.029454.
- 45. Tesema GA, Mekonnen TH, Teshale AB. (2020) Individual and community-level
 determinants, and spatial distribution of institutional delivery in Ethiopia, 2016: Spatial
 and multilevel analysis. PLoS ONE 15(11): e0242242.
- 46. Lubega P, Nalugya SJ, Kimuli AN, Twinokusiima M, Khasalamwa M, Kyomugisa R,
 et.al. Adherence to viral load testing guidelines, barriers, and associated factors among
 persons living with HIV on ART in Southwestern Uganda: a mixed-methods study.
 BMC Public Health. 2022 Jun 29;22(1):1268. doi: 10.1186/s12889-022-13674-z.
- 47. Bocage AE, Coelho LE, Lake JE, Clark JL, Torres TS, Jalil EM, et al. The Impact of
 COVID-19 on HIV Care in Rio de Janeiro, Brazil 2019–2021: Disparities by Age and
 Gender. AIDS Behav (2023). https://doi.org/10.1007/s10461-023-03988-3
- 48. Costa JM, Torres TS, Coelho LE, Luz PM. Adherence to antiretroviral therapy for
 HIV/AIDS in Latin America and the Caribbean: Systematic review and meta-analysis.
 J Int AIDS Soc. 2018 Jan;21(1):e25066. doi: 10.1002/jia2.25066
- 49. Harlow AF, Bor J, Brennan AT, Maskew M, MacLeod W, Carmona S, et.al. Impact of
 Viral Load Monitoring on Retention and Viral Suppression: A Regression Discontinuity
 Analysis of South Africa's National Laboratory Cohort. Am J Epidemiol. 2020 Dec
 1;189(12):1492-1501. doi: 10.1093/aje/kwaa140
- 50. Hall HI, Tang T, Westfall AO, Mugavero MJ. (2013). HIV care visits and time to viral
 suppression, 19 U.S. jurisdictions, and implications for treatment, prevention and the
 national HIV/AIDS strategy. PloS one, 8(12), e84318.
 https://doi.org/10.1371/journal.pone.0084318

51. Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC. The effect on treatment comparisons
of different measurement frequencies in human immunodeficiency virus observational
databases. Am J Epidemiol. 2006 Apr 1;163(7):676-83. doi: 10.1093/aje/kwj083. Epub
2006 Feb 16. PMID: 16484448.

- 52. Feller DJ, Agins BD. (2017). Understanding Determinants of Racial and Ethnic
 Disparities in Viral Load Suppression. Journal of the International Association of
 Providers of AIDS Care, 16(1), 23–29. https://doi.org/10.1177/2325957416667488
- 53. Flynn AG, Anguzu G, Mubiru F, Kiragga AN, Kamya M, Meya DB, et.al. Socioeconomic
 position and ten-year survival and virologic outcomes in a Ugandan HIV cohort
 receiving antiretroviral therapy. PLoS One. 2017 Dec 15;12(12):e0189055. doi:
 10.1371/journal.pone.0189055. PMID: 29244807; PMCID: PMC5731768.
- 54. Xia Q, Robbins RS, Lazar R, Torian LV, Braunstein SL. Racial and socioeconomic
 disparities in viral suppression among persons living with HIV in New York City. Ann
 Epidemiol. 2017 May;27(5):335-341. doi: 10.1016/j.annepidem.2017.04.005.
- 55. López JD, Qiao Q, Presti RM, Hammer RA, Foraker RE. The impact of neighborhood
 socioeconomic status on retention in care and viral suppression among people living
 with HIV. AIDS Care. 2022 Nov;34(11):1383-1389. doi:
 10.1080/09540121.2022.2040724. Epub 2022 Feb 14. PMID: 35164602.
- 56. Tymejczyk O, Jamison K, Pathela P, Braunstein S, Schillinger JA, Nash D. HIV Care
 and Viral Load Suppression After Sexual Health Clinic Visits by Out-of-Care HIVPositive Persons. AIDS Patient Care STDS. 2018 Oct;32(10):390-398. doi:
 10.1089/apc.2018.0097. PMID: 30277815; PMCID: PMC6198765.
- 57. Mocroft A, Lundgren J, Antinori A, Monforte AD, Brännström J, Bonnet F, et al. Late
 presentation for HIV care across Europe: update from the Collaboration of
 Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
 Euro Surveill. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30070.
- 58. UNAIDS, Global AIDS Uptade Seizing the moment. Tackling entrenched inequalities
 to end epidemics. Geneve, 2020..

- 59. Rodrigues A, Struchiner CJ, Coelho LE, Veloso VG, Grinsztejn B, et al. (2021). Late
 initiation of antiretroviral therapy: inequalities by educational level despite universal
 access to care and treatment. BMC Public Health, 21 (1), S. 389.
 http://doi.org/10.1186/s12889-021-10421-8
- 656 60. Barr DA, Lewis JM, Feasey N, Schutz C, Kerkhoff AD, Jacob, ST, et al. Mycobacterium
 657 tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in
 658 seriously ill adults with HIV: a systematic review and meta-analysis of individual patient
 659 data. Lancet Infect Dis. 2020;20(6):742-752. doi:10.1016/S1473-3099(19)30695-4.
- 660 61. dos Santos DT, Arroyo LH, Alves YM, Alves LS, Berra TZ, Crispim JA, et al. Survival
 661 time among patients who were diagnosed with tuberculosis, the precocious deaths and
 662 associated factors in southern Brazil. Trop Med Health. 2021;49(1):31. Published 2021
 663 Apr 21. doi:10.1186/s41182-021-00320-4
- 664 62. World Health Organization. Global tuberculosis report 2021. Geneva: World Health
 665 Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO
- 666 63. Magnabosco GT, Lopes LM, Andrade RL de P, Brunello MEF, Monroe AA, Villa TCS.
 667 Tuberculosis control in people living with HIV/AIDS. Rev Latino-Am Enfermagem
 668 [Internet]. 2016;24:e2798. Available from: https://doi.org/10.1590/1518669 8345.1187.2798
- 670 64. Saraceni V, Benzaken AS, Pereira G, Andrade KB, Oliveira PB, Arakaki-Sanchez D,
 671 et.al. (2018). Tuberculosis burden on AIDS in Brazil: A study using linked databases.
 672 PloS one, 13(11), e0207859. https://doi.org/10.1371/journal.pone.0207859.
- 673 65. Cutrell J, Jodlowski T, Bedimo R. The management of treatment-experienced HIV
 674 patients (including virologic failure and switches). Ther Adv Infect Dis.
 675 2020;7:2049936120901395. Published 2020 Jan 20. doi:10.1177/2049936120901395
 66. McComsey GA, Lingohr-Smith M, Rogers R, Lin J, Donga P. Real-World Adherence
- to Antiretroviral Therapy Among HIV-1 Patients Across the United States. Adv Ther.
 2021 Sep;38(9):4961-4974. doi: 10.1007/s12325-021-01883-8. Epub 2021 Aug 14.

679 67. Nemes MIB, Alves AM. Relatório Qualiaids 2017. Sistema de avaliação Qualiaids. São

680 Paulo: Faculdade de Medicina da USP, Departamento de Medicina Preventiva; 2016

- 681 [cited on May 2023]. Available on:
- 682 https://equipequaliaids.wixsite.com/qualiaids/publica%C3%A7%C3%B5es
- 68. O'Neill M, Karelas GD, Feller DJ, Knudsen-Strong E, Lajeunesse D, et.al. (2015). The
 684 HIV Workforce in New York State: Does patient volume Correlate with quality? Clinical
 685 Infectious Diseases, 61(12),1871–1877.
- 686 69. Nemes MIB, Castanheira ERL, Melchior R, Alves MTSSB, Basso CR. (2004).
 687 Avaliação da qualidade da assistência no programa de AIDS: questões para a
 688 investigação em serviços de saúde no Brasil. Cadernos de Saúde Pública, 20(Suppl.
- 689 2), S310-S321. https://dx.doi.org/10.1590/S0102-311X2004000800024
- 70. Nemes MIB, Melchior R, Basso CR, Castanheira ERL, Alves MTSSB, Conway S. The
 variability and predictors of quality of AIDS care services in Brazil. BMC Health Serv
 Res 9, 51 (2009). https://doi.org/10.1186/1472-6963-9-51
- 71. Mugavero MJ, Napravnik S, Cole SR, Eron JJ, Lau B, Crane HM, et.al. Viremia copyyears predicts mortality among treatment-naive HIV-infected patients initiating
 antiretroviral therapy. Clin Infect Dis. 2011 Nov;53(9):927-35. doi: 10.1093/cid/cir526.
 Epub 2011 Sep 2. PMID: 21890751; PMCID: PMC3189165.
- 697 72. World Health Organization. The role of HIV viral suppression in improving individual
 698 health and reducing transmission: policy brief. ISBN 978-92-4-005517-9 electronic
 699 version. © World Health Organization 2023
- 700 73. Bouabida K, Chaves BG, Anane E. Challenges and barriers to HIV care engagement
 701 and care cascade: viewpoint. Front Reprod Health. 2023 Jul 20;5:1201087. doi:
 702 10.3389/frph.2023.1201087.
- 703 74. Meireles MV, Pascom ARP, Duarte EC, McFarland W. Comparative effectiveness of
 704 first-line antiretroviral therapy: results from a large real-world cohort after the
 705 implementation of dolutegravir. AIDS. 2019 Aug 1;33(10):1663-1668. doi:
 706 10.1097/QAD.0000000002254.

- 707 75. Michienzi SM, Barrios M, Badowski ME. Evidence Regarding Rapid Initiation of
 708 Antiretroviral Therapy in Patients Living with HIV. Curr Infect Dis Rep 23, 7 (2021).
 709 https://doi.org/10.1007/s11908-021-00750-5
- 710 76. Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, et.al.
 711 Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin Trials. 2017
 712 May:18(3):100-109. doi: 10.1080/15284336.2017.1311056. Epub 2017 Apr 7.
- 713 77. Colasanti J, Sumitani J, Mehta CC, Zhang Y, Nguyen ML, Del Rio C, Armstrong WS.
 714 Implementation of a Rapid Entry Program Decreases Time to Viral Suppression
 715 Among Vulnerable Persons Living With HIV in the Southern United States. Open
 716 Forum Infect Dis. 2018 Jun 28;5(6):ofy104. doi: 10.1093/ofid/ofy104. PMID: 29992172;
 717 PMCID: PMC6022569.
- 718 78. Girometti N, Lander F, McOwan A, Nwokolo N, Boffito M, Whitlock G. and (2020),
 719 Rapid ART start in early HIV infection: Time to viral load suppression and retention in
 720 care in a London cohort. HIV Med, 21: 613-615. https://doi.org/10.1111/hiv.12900
- 721 79. Pham MD, Nguyen HV, Anderson D, Crowe S, Luchters S. Viral load monitoring for
 722 people living with HIV in the era of test and treat: progress made and challenges ahead
 723 a systematic review. BMC Public Health. 2022 Jun 16;22(1):1203. doi:
 724 10.1186/s12889-022-13504-2. PMID: 35710413; PMCID: PMC9202111.



Figure1



Figure2

North

Number of facilities: 45 (4.8%)

- in metropolitan area or state capital: 21 (46.7%)
- outside a metropolitan area: 24 (53.3%)
- PLWHA who initiated ART: 13,512 (10.5%)

Northeast Number of facilities: 123 (13.1%)

- in metropolitan area or state capital: 61 (49.6%)

medRxiv preprint doi: https://doi.org/10.1101/2024.05.30.24308200; this version posted May 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Outside a metropolitan area: 62 (50.4%) It is made available under a CC-BY 4.0 International license .

PLWHA who initiated ART: 24,017 (18.7%)

Central-West Number of facilities: 40 (4.3%)

- in metropolitan area or state capital: 18 (45.0%)
- outside a metropolitan area: 22 (55.0%)

PLWHA who initiated ART: 8,863 (6.9%)

Southeast

Number of facilities: 555 (59.0%)

- in metropolitan area or state capital: 399 (71.9%)
- outside a metropolitan area: 156 (28.1%)
- PLWHA who initiated ART: 52,638 (41.0%)

South

Number of facilities: 178 (18.9%)

- In metropolitan area or state capital: 124 (69.7%)
- outside a metropolitan area: 54 (30.3%)
- PLWHA who initiated ART: 29,330 (22.8%)

Number of facilities	Central-West		Northeast		North		Southeast		South		Total	
ranked by size	n	%	n	%	n	%	n	%	n	%	n	%
Up to 50 persons	6	15.0	33	26.8	8	17.8	306	55.1	44	24.7	397	42.2
51 to 500 persons	27	67.5	72	58.5	28	62.2	219	39.5	115	64.6	461	49.0
More than 500 persons	7	17.5	18	14.6	9	20.0	30	5.4	19	10.7	83	8.8
Total	40	100.0	123	100.0	45	100.0	555	100.0	178	100.0	941	100.0

Figure3